{{unreferenced|date=August 2016}}
{{Chembox
| ImageFile = Imeglimin.svg
| ImageSize = 150px
| IUPACName = (2''S'')-''N''<sup>6</sup>,''N''<sup>6</sup>,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
| OtherNames = 
|Section1={{Chembox Identifiers
| CASNo = 775351-65-0
| PubChem = 
| ChemSpiderID = 26232690
| SMILES = C[C@H]1NC(=NC(=N1)N)N(C)C
| InChI = 1/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
| InChIKey = GFICWFZTBXUVIG-SCSAIBSYBC
| StdInChI = 1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
| StdInChIKey = GFICWFZTBXUVIG-SCSAIBSYSA-N
  }}
|Section2={{Chembox Properties
| C=6 | H=13 | N=5
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}

'''Imeglimin''' is an experimental drug being developed as an oral [[anti-diabetic]]. It is an [[oxidative phosphorylation]] blocker that acts to inhibit hepatic [[gluconeogenesis]], increase muscle [[glucose]] uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.

==References==
{{reflist}}

[[Category:Anti-diabetic drugs]]


{{gastrointestinal-drug-stub}}